GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » EV-to-EBITDA

Harbin Medisan Pharmaceutical Co (SZSE:002900) EV-to-EBITDA : 121.31 (As of May. 29, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Harbin Medisan Pharmaceutical Co's enterprise value is ¥4,523 Mil. Harbin Medisan Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ¥37 Mil. Therefore, Harbin Medisan Pharmaceutical Co's EV-to-EBITDA for today is 121.31.

The historical rank and industry rank for Harbin Medisan Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

SZSE:002900' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99.19   Med: 16.22   Max: 136.75
Current: 121.31

During the past 13 years, the highest EV-to-EBITDA of Harbin Medisan Pharmaceutical Co was 136.75. The lowest was -99.19. And the median was 16.22.

SZSE:002900's EV-to-EBITDA is ranked worse than
95.63% of 733 companies
in the Drug Manufacturers industry
Industry Median: 13.88 vs SZSE:002900: 121.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-29), Harbin Medisan Pharmaceutical Co's stock price is ¥13.66. Harbin Medisan Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.040. Therefore, Harbin Medisan Pharmaceutical Co's PE Ratio (TTM) for today is 341.50.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Harbin Medisan Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co EV-to-EBITDA Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.08 10.58 21.84 18.78 15.88

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.45 40.41 37.09 15.88 88.14

Competitive Comparison of Harbin Medisan Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Medisan Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Medisan Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Medisan Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Harbin Medisan Pharmaceutical Co's EV-to-EBITDA falls into.


;
;

Harbin Medisan Pharmaceutical Co EV-to-EBITDA Calculation

Harbin Medisan Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4523.259/37.287
=121.31

Harbin Medisan Pharmaceutical Co's current Enterprise Value is ¥4,523 Mil.
Harbin Medisan Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Medisan Pharmaceutical Co  (SZSE:002900) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Harbin Medisan Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.66/0.040
=341.50

Harbin Medisan Pharmaceutical Co's share price for today is ¥13.66.
Harbin Medisan Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.040.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Harbin Medisan Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Medisan Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co Headlines

No Headlines